Five decades of clinical ABO-incompatible liver transplantation research: a bibliometric analysis
- PMID: 39093832
- PMCID: PMC11745713
- DOI: 10.1097/JS9.0000000000001987
Five decades of clinical ABO-incompatible liver transplantation research: a bibliometric analysis
Conflict of interest statement
The authors declare no conflicts of interest.
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Figures


References
-
- Egawa H, Oike F, Buhler L, et al. . Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. Transplantation 2004;77:403–411. - PubMed
-
- Yamamoto H, Uchida K, Kawabata S, et al. . Feasibility of monotherapy by rituximab without additional desensitization in ABO-incompatible living-donor liver transplantation. Transplantation 2018;102:97–104. - PubMed
-
- Piro LD, White CA, Grillo-López AJ, et al. . Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1999;10:655–661. - PubMed
-
- Monteiro I, McLoughlin LM, Fisher A, et al. . Rituximab with plasmapheresis and splenectomy in abo-incompatible liver transplantation. Transplantation 2003;76:1648–1649. - PubMed
-
- Song GW, Lee SG, Hwang S, et al. . ABO-incompatible adult living donor liver transplantation under the desensitization protocol with rituximab. Am J Transplant 2016;16:157–170. - PubMed
LinkOut - more resources
Full Text Sources